TNFRSF8 and cancer: Furthermore, the significant upregulation of TNFRSF8 (CD30) in cancer cell lines but not in normal HSF cells highlights Brentuximab’s selectivity for CD30-expressing malignant cells, reinforcing the observations of Kang et al. (2021) and Zhang et al. (2022), who documented the drug’s effectiveness in targeting CD30-positive cells.